Xarelto approval in SPAF in US- A step forward to be a market leader in anticoagulant space
We close our positive investment alert on Bayer - post approval of Xarelto in SPAF by the USFDA. The stock has given a stellar ~27% returns (From €36.5 to €46.88) since our positive investment alert recommendation issued on 6th September (on release of negative FDA briefing documents leading to ~13% crash in Bayer’s stock price). Xarelto is approved with broad label to use in all NVAF patients, however without superiority claim to warfarin, and with boxed warning of increased risk of stroke on discontinuation in US. Xarelto’s once daily oral advantage (taken with meal at night) and approved label will make it an anticoagulant of choice atleast in high risk subgroups (CHADS2 score=4, 5, 6) and in patients who are not well controlled on warfarin.
COMPANIES MENTIONED
PFIZER, BRISTOL MYERS SQUIBB, JOHNSON & JOHNSON, BAYER
PFIZER, BRISTOL MYERS SQUIBB, JOHNSON & JOHNSON, BAYER
